Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury

Matt S. Zinter, Caroline A. Lindemans, Birgitta A. Versluys, Madeline Y. Mayday, Sara Sunshine, Gustavo Reyes, Marina Sirota, Anil Sapru, Michael A. Matthay, Sandhya Kharbanda, Christopher C. Dvorak, Jaap J. Boelens, Joseph L. DeRisi

Blood (2021) 137 (12): 1679–1689.

https://doi.org/10.1182/blood.2020009246

Published: 2021

Includes: Supplemental data

Journal Articles

Primary Prophylaxis Using Peg-Filgrastim Is Useful Preventing Severe Infections and Neutropenia in Patients Diagnosed with Non Hodgkin Lymphoma (NHL). Report of Latin America International Multicenter Study

Luis Villela, MD, Alberto Villalobos, MD, Gustavo Reyes-Brena, MD, Jorge Duque, MD, Juan Carlos Solís-Poblano, Eduardo Reynoso, MD, Roberto Ovilla, MD, Alejandro Camacho, MD, Norberto Vazquez, MD, Oscar Garces, Enrique Pedrasa, MD, Salvador Silva, MD

Blood (2008) 112 (11): 4663.

https://doi.org/10.1182/blood.V112.11.4663.4663

Published: 2008

Journal Articles

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Blood (2008) 112 (11): 4275.

https://doi.org/10.1182/blood.V112.11.4275.4275

Published: 2008

Journal Articles

Efficacy and Safety of Rituximab+CHOP in IR and Maintenance Therapy with Rituximab vs Observation in De Novo Aggressive Non-Hodgkin Lymphoma.

Francisco Tripp, MD, Enrique Báez, MD, Elsa Ávila, MD, Severiano Baltazar, MD, Oscar Garcés, MD, Gustavo Reyes, MD, Benjamín Batista, MD, Alva Zaragoza, MD, Jorge Vela-Ojeda, MD, Luis Villela, MD

Blood (2007) 110 (11): 4489.

https://doi.org/10.1182/blood.V110.11.4489.4489

Published: 2007

Journal Articles

Compassionate Use of Nilotinib (AMN107) in Mexican Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib.

Manuel Ayala, MD, Rafael Hurtado, MD, Kevin Nacho, MD, Norma Tapia, MD, Martha Alvarado, MD, Alvaro Aguayo, MD, Sergio Cleto, MD, Yolanda Lugo, MD, Gustavo Reyes, MD, Pablo Vargas, MD, Angel Herrera, Luis Antonio Meillon, MD

Blood (2007) 110 (11): 4578.

https://doi.org/10.1182/blood.V110.11.4578.4578

Published: 2007

Journal Articles

Is First Line Single Agent Rituximab the Best Treatment for Indolent Non-Hodgkin’s Lymphoma? Update of a Multicentric Study Comparing Rituximab vs CNOP vs Rituximab Plus CNOP.

Silvia Rivas-Vera, MD, Enrique Baez, MD, Pedro Sobrevilla-Calvo, MD, Severiano Baltazar, MD, Francisco Tripp, MD, Jorge Vela, MD, Oscar Garces, MD, Luis Aguilar, MD, Gregorio Ignacio, MD, Jorge Duque, MD, Petty Rodriguez, MD, Gustavo Reyes, MD

Blood (2005) 106 (11): 2431.

https://doi.org/10.1182/blood.V106.11.2431.2431

Published: 2005

Journal Articles

Virological and Immunological Features of Long-Term Human Immunodeficiency Virus–Infected Individuals Who Have Remained Asymptomatic Compared With Those Who Have Progressed to Acquired Immunodeficiency Syndrome

Edward Barker, Carl E. Mackewicz, Gustavo Reyes-Terán, Akihiko Sato, Sharon A. Stranford, Sue H. Fujimura, Cindy Christopherson, Sheng-Yung Chang, Jay A. Levy

Blood (1998) 92 (9): 3105–3114.

https://doi.org/10.1182/blood.V92.9.3105

Published: 1998

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury

Primary Prophylaxis Using Peg-Filgrastim Is Useful Preventing Severe Infections and Neutropenia in Patients Diagnosed with Non Hodgkin Lymphoma (NHL). Report of Latin America International Multicenter Study

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Efficacy and Safety of Rituximab+CHOP in IR and Maintenance Therapy with Rituximab vs Observation in De Novo Aggressive Non-Hodgkin Lymphoma.

Compassionate Use of Nilotinib (AMN107) in Mexican Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib.

Is First Line Single Agent Rituximab the Best Treatment for Indolent Non-Hodgkin’s Lymphoma? Update of a Multicentric Study Comparing Rituximab vs CNOP vs Rituximab Plus CNOP.

Virological and Immunological Features of Long-Term Human Immunodeficiency Virus–Infected Individuals Who Have Remained Asymptomatic Compared With Those Who Have Progressed to Acquired Immunodeficiency Syndrome

Email alerts

ASH Publications

American Society of Hematology

Update search

The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury

Primary Prophylaxis Using Peg-Filgrastim Is Useful Preventing Severe Infections and Neutropenia in Patients Diagnosed with Non Hodgkin Lymphoma (NHL). Report of Latin America International Multicenter Study

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Efficacy and Safety of Rituximab+CHOP in IR and Maintenance Therapy with Rituximab vs Observation in De Novo Aggressive Non-Hodgkin Lymphoma.

Compassionate Use of Nilotinib (AMN107) in Mexican Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib.

Is First Line Single Agent Rituximab the Best Treatment for Indolent Non-Hodgkin’s Lymphoma? Update of a Multicentric Study Comparing Rituximab vs CNOP vs Rituximab Plus CNOP.

Virological and Immunological Features of Long-Term Human Immunodeficiency Virus–Infected Individuals Who Have Remained Asymptomatic Compared With Those Who Have Progressed to Acquired Immunodeficiency Syndrome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only